DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
66	IgA腎症	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02571842 (ClinicalTrials.gov)	January 2012	6/10/2015	Rituximab in Recurrent IgA Nephropathy	A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology	Recurrent IgA Nephropathy	Drug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroids	Chulalongkorn University	NULL	Recruiting	18 Years	70 Years	Both	30	Phase 4	Thailand
2	NCT00498368 (ClinicalTrials.gov)	February 2009	9/7/2007	Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy	A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy	IgA Nephropathy	Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement	Mayo Clinic	Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen	Completed	18 Years	70 Years	All	34	Phase 4	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02571842
(ClinicalTrials.gov)

January 2012

6/10/2015

Rituximab in Recurrent IgA Nephropathy

A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology

Recurrent IgA Nephropathy

Drug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroids

Chulalongkorn University

NULL

Recruiting

18 Years

70 Years

Both

Phase 4

Thailand

NCT00498368
(ClinicalTrials.gov)

February 2009

9/7/2007

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy

IgA Nephropathy

Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement

Mayo Clinic

Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen

Completed

18 Years

70 Years

All

Phase 4

United States